Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Synthorx Inc. (NASDAQ:THOR) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics Inc.	N/A	0.00	8.29M	-0.42	0.00
Synthorx Inc.	N/A	0.00	30.64M	-1.01	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Brainstorm Cell Therapeutics Inc. and Synthorx Inc.

Profitability

Table 2 provides Brainstorm Cell Therapeutics Inc. and Synthorx Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics Inc.	0.00%	-101.8%	-59.6%
Synthorx Inc.	0.00%	0%	0%

Liquidity

The current Quick Ratio of Brainstorm Cell Therapeutics Inc. is 3.3 while its Current Ratio is 3.3. Meanwhile, Synthorx Inc. has a Current Ratio of 0.8 while its Quick Ratio is 0.8. Brainstorm Cell Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Synthorx Inc.

Institutional and Insider Ownership

Institutional investors held 12.2% of Brainstorm Cell Therapeutics Inc. shares and 90.1% of Synthorx Inc. shares. Brainstorm Cell Therapeutics Inc.’s share held by insiders are 0.9%. Comparatively, 18.1% are Synthorx Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Brainstorm Cell Therapeutics Inc.	-4.2%	5.72%	27.21%	-3%	26.8%	9.3%
Synthorx Inc.	1.5%	39.46%	0%	0%	0%	13.06%

For the past year Brainstorm Cell Therapeutics Inc.’s stock price has smaller growth than Synthorx Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.